Results 161 to 170 of about 59,829 (305)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren   +8 more
wiley   +1 more source

Caffeine and Headache: Exploring the Multifaceted Relationship. [PDF]

open access: yesBrain Behav
Hussein M   +6 more
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

open access: yesBritish Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

OnabotulinumtoxinA for chronic migraine: a critical appraisal

open access: yes, 2015
Rubesh Gooriah, Fayyaz Ahmed Department of Neurology, Hull Royal Infirmary, Kingston Upon Hull, UK Abstract: Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options.
Ahmed F, Gooriah R
core  

The prevalence of comorbid migraine in multiple sclerosis: do multiple sclerosis and migraine really coexist? [PDF]

open access: yesJ Oral Facial Pain Headache
Kępczyńska K   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy